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Background: Inflammation plays an important role in the pathogenesis of atherosclerosis. The link between rheumatoid
arthritis (RA) and an increased risk of cardiovascular disease and mortality is well established; however, the association
between inflammatory bowel disease (IBD) and cardiovascular risk is controversial. Arterial stiffness is both a marker and
risk factor for atherosclerosis. Here we aimed to 1) compare circulating markers of inflammation and endothelial
dysfunction, traditional cardiovascular risk factors, and arterial stiffness between RA and IBD to help to understand
their different associations with cardiovascular disease; 2) assess the impacts of circulating markers of
inflammation and endothelial dysfunction, and traditional risk factors on arterial stiffness.
Methods: Patients with RA (n = 43) and IBD (n = 42), and control subjects (n = 73) were recruited. Plasma inflammatory
markers and von Willebrand factor (vWF) were measured by Multiplex assays or ELISA. Arterial stiffness was determined
by brachial-ankle pulse wave velocity (baPWV) and ankle-brachial index (ABI) was measured. Framingham Risk Score (FRS)
was calculated, and other traditional risk factors were also documented.
Results: Plasma levels of several inflammatory markers and vWF were significantly but comparably elevated in RA and
IBD compared with controls, except for a higher level of C-reactive protein (CRP) in RA than IBD. Compared to controls,
FRS, body mass index, waist circumference, and triglycerides were increased in RA, but not in IBD. baPWV did not
significantly differ among 3 groups, while ABI was modestly but significantly lower in IBD than controls. Circulating
markers (macrophage migration inhibitory factor, tumour necrosis factor-α, CRP, and vWF) were significantly associated
with baPWV. However, traditional risk factors (age, systolic blood pressure, body mass index, diabetes and triglycerides)
were the parameters associated with baPWV in multiple regression analyses (overall r = 0.866, p < 0.001).
Conclusions: RA has a higher level of CRP and more pronounced traditional cardiovascular risk factors than IBD, which
may contribute to the difference in their associations with cardiovascular disease and mortality. Traditional risk factors,
rather than inflammation markers, are major predictors of arterial stiffness even in subjects with inflammatory disorders.
Our results point to the importance of modifying traditional risk factors in patients with inflammatory disorders.
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It is well known that inflammation plays a pivotal role in
the pathogenesis and progression of atherosclerosis and
that measures of systemic inflammation, such as circulating
C-reactive protein (CRP) and interleukin (IL)-6, provide
useful prognostic information for atherosclerosis [1-4].
Chronic inflammatory diseases such as rheumatoid arth-
ritis (RA) have been strongly linked to accelerated athero-
sclerosis and increased incidence of cardiovascular events
and mortality [5-8]. Such increased cardiovascular risk
in RA cannot be completely explained by traditional car-
diovascular risk factors [5]. In patients with inflammatory
bowel disease (IBD, ulcerative colitis (UC) and Crohn’s
disease (CD)), however, association with the risk of car-
diovascular disease is controversial. While the majority
of studies showed no evidence for an increased risk of
cardiovascular disease and mortality in IBD [9-11], this
is not a universal finding [12]. In chronic inflammatory
conditions, proinflammatory cytokines and a systemic in-
flammatory state play a crucial role in accelerated athero-
sclerosis and the development of cardiovascular events.
The chronic and systemic inflammation can induce endo-
thelial activation and dysfunction, which may amplify ath-
erosclerosis in chronic inflammatory conditions. Whether
there are differences in proinflammatory cytokines and
endothelial dysfunction markers which can account for
any differences in their susceptibility to atherosclerosis
is yet to be explored.
Large artery stiffness is known to be increased in patients
with atherosclerosis and it is both a surrogate marker and
an independent risk factor for atherosclerosis [13-15].
Aortic PWV (commonly the carotid-femoral PWV) is
accepted as the “gold standard” measure of arterial stiff-
ness. Brachial-ankle PWV (baPWV) is, however, a promis-
ing technique to measure arterial stiffness conveniently
and more suited to routine clinical use than some other
more intrusive or complicated approaches [16,17]. In
addition, the presence of vascular morphological changes,
such as increased carotid intima-media thickness and the
presence of carotid plaque, and the consequences of
stenosis, such as reduced ankle-brachial index (ABI),
have also been found to have diagnostic and predictive
value [18,19]. In chronic inflammatory diseases, elevated
proinflammatory cytokines may promote vascular changes
and increase arterial stiffness, and subsequently contribute
to increased risk for cardiovascular disease. Whether these
two diseases elicit different vascular changes is unclear.
We therefore aimed to compare circulating markers of
inflammation and endothelial dysfunction, and arterial
properties (baPWV, upstroke time (UT) of the ankle pulse
pressure and ABI), as well as traditional risk factors be-
tween RA and IBD in an attempt to understand the differ-
ent associations with cardiovascular disease between these
two inflammatory conditions. Furthermore, we aimed toexamine the impacts of traditional risk factors, and cir-
culating markers of inflammation and endothelial dys-
function on vascular changes to better understand the
underlying mechanism for accelerated atherosclerosis in
inflammatory conditions.
Materials and methods
The study was approved by the Human Ethics Research
Committee of the Alfred Hospital and all subjects provided
written informed consent prior to their participation.
All clinical investigation was conducted according to the
principles expressed in the Declaration of Helsinki.
Subjects
Patients with RA (n = 43) and IBD (n = 42, UC: 40% and
CD: 60%) were recruited from the respective clinics at
the Alfred Hospital. RA patients fulfilled the diagnostic
criteria for the presence of RA proposed by the American
Rheumatism Associations [20]. The diagnosis of IBD was
established by gastroenterologists based on clinical, labora-
tory, radiological, endoscopic and histological criteria.
Patients in our study were assessed at disease specific spe-
cialist clinics of the Alfred Hospital by Royal Australian
College of Physicians accredited specialists. Age- and
gender-matched healthy volunteers (n = 73) were recruited
from the risk evaluation clinic of Baker IDI Heart and
Diabetes Institute. Patients and controls were older than
35 years. Subjects with known cerebrovascular, coronary
or peripheral vascular disease were excluded. Subjects’
demographics, medical and medication history were
documented. Among RA patients, disease activity was
assessed by the severity of joint pain, stiffness, and
swelling. Disease activity in CD patients was assessed
by the Harvey Bradshaw Index (HBI), while in UC patients
was assessed by the criteria of “Truelove-Witts”. The
majority of patients with RA or IBD received disease
modifying therapy in addition to symptomatic treatment.
Common treatments for the IBD group at the time of
their vascular study included azathiaprine (n = 11, 26%),
sulphasalazine (n = 9, 24%), melasamine (n = 9, 24%), 6-
mercapto-purine (n = 6, 14%) and biologics (n = 6, 14%).
Amongst the RA group common treatments included
methotrexate (n = 17, 40%), biologics (n = 12, 28%), and
plaquenil (n = 5, 12%). Biologics include tumour necrosis
factor-α (TNF-α) and IL-6 antagonists. Other treatments
included systemic and/or local corticosteroids (RA: n = 11,
25.6%, and IBD: n = 7, 16.7%), and non-steroidal anti-
inflammatory agents (RA: n = 3, 7% and IBD: 0%).
Vascular measures
baPWV, UT of pulse wave and ABI were measured in a
quiet environment using an automated oscillometric ma-
chine, the Colin VP-1000 Plus. A phonocardiogram sensor
was placed over the mid-point of patients’ third ribs and
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each wrist. baPWV was measured simultaneously and
bilaterally with the use of these sensors and four blood
pressure cuffs with multihead pressure transducers placed
over the brachial and posterior tibial arteries. Based on
patients’ height, baPWV was calculated using the assess-
ment of pulse transit time between the brachial and
posterior tibial arteries. Similarly, ABI was calculated
simultaneously and bilaterally as the ratio of the systolic
blood pressure of the posterior tibial and brachial arteries.
Two measurements of ABI and baPWV were taken, and
the average of the two recorded. Analyses of baPWV and
UT were undertaken using the average of the left and right
whilst for ABI analyses were performed using the lowest
value.
Traditional risk factors
Fasting plasma lipids (total cholesterol, triglycerides, low-
density lipoprotein cholesterol (LDL-C) and high-density
lipoprotein cholesterol (HDL-C)) and glucose were deter-
mined at the Department of Chemical Pathology of the
Alfred Hospital. The blood pressures reported were all
obtained in the morning after an overnight fast and at
the same visit as their vascular assessment. Blood pres-
sures were measured in the seated position using an au-
tomated sphygmomanometer (HEM-907; Omron). Three
readings, one minute apart, were taken and the average of
last 2 readings was used. If the first reading was abnormal,
then the second reading was 4 minutes apart. For each
participant, a FRS for 10-year ‘hard’ coronary heart disease
endpoints was calculated (see http://cvdrisk.nhlbi.nih.gov/
calculator.asp).
Plasma markers
Plasma levels of TNF-α, IL-6, IL-1β, IL-10, and von
Willebrand factor (vWF) were measured using multiplex
kits from Millipore according to the manufacturer’s in-
struction. The appropriate cytokine standards, plasma
samples (25 μL), and fluorescent conjugated, antibody-
immobilized beads were added to wells of a pre-wet fil-
tered plate and then incubated overnight at 4°C. The
following day, the plate was washed twice with wash buffer
and then incubated with secondary detection antibody for
1 h, followed by subsequent incubation with strepavidin-
PE for 30 min. After the plate was washed twice again with
wash buffer, it was run on the Luminex system (Biorad)
with the addition of sheath fluid. Concentrations of differ-
ent analytes in the plasma samples were determined by
using respective standard curves generated in the multiplex
assays. Neat plasma samples were used for all assays except
for vWF (1:10,000 dilutions, using assay buffer provided in
the kit).
Macrophage migration inhibitory factor (MIF) in plasma
was measured using commercial ELISA kits (R&D System)according to the manufacturer’s instructions. All samples
and standards were measured in duplicate and averages
used. High-sensitivity CRP in plasma was measured at the
Department of Chemical Pathology of the Alfred Hospital.
E-selectin+ endothelial microparticles (EMPs) were mea-
sured by flow cytometry in plasma. In brief, plasma was
thawed completely and centrifuged at 16,000 g for 5 min at
4°C to deplete platelets or any cell debris. 100 μL aliquot
was incubated with 10 μL of FITC-labelled anti-human
E-selectin antibody (clone: BBIG-E5, R & D Systems) or
a corresponding mouse IgG isotype (R & D Systems) at
room temperature for 20 min with gentle shaking. At
the end of incubation, 300 μL of double filtered 0.2%
FBS/PBS (filtered through a 0.2 μm and then a 0.1 μm
membrane filter) was added and samples were counted
with a Canto II flow cytometer (BD Biosciences) for 5 min.
Megamix beads (Biocytex, France), a mixture of 0.5 μm,
0.9 μm, and 3 μm beads, were used for size calibration
according to the manufacture’s instruction. For EMP
enumeration, 30 μL of diluted calibration beads (BD
Biosciences, USA) was added to each FACS tube and a
formula was used based on the concentration of the added
calibration beads [21], which discriminated themselves
from the EMP population on the FSC-SSC cytogram. All
counting data were then analysed using FlowJo software
(Tree Star). Results were presented as counts of E-selectin+
EMP per μL of plasma.
Statistical analysis
Continuously variable data are presented as mean ± SD
for normally distributed data or median (25, 75 percentile)
for non-normally distributed data. Categorical data is
presented as percentage, and analysed by χ2. Continu-
ously variable data were evaluated for normality using
the Kolmogorov-Smirnov (K-S) test. Between-group ana-
lysis was performed by ANOVA, followed by scheffé test
for normally distributed data, or by Kruskal-Walis test for
non-normally distributed data. Bivariate correlations were
assessed with Pearson correlation coefficient for normally
distributed data and Spearman rank correlation coefficient
for non-normally distributed data, respectively. Multiple
regression analysis was undertaken using stepped entry
and removal with Pin set at p = 0.1 and Pout at p = 0.05.
Skewed data was Ln transformed prior to inclusion in
multiple regression analyses. All statistical analyse were
performed using SPSS v19 and statistical significance was
set at p < 0.05 (two-sided).
Results
Demographic characteristics and traditional risk factors
The groups were well matched by age and gender. Systolic
and diastolic blood pressure, body mass index (BMI), waist
circumference and triglycerides were significantly higher
in patients with RA compared to controls. Smoking was
Table 2 Change of circulating inflammatory and
endothelial markers
Control RA IBD
CRP, μg/mL 0.90 (9.50, 2.00) 3.8 (0.7, 7.9)*** 1.70 (0.70, 4.05)*#
IL-1β, pg/mL 0.74 (0.31, 1.23) 0.87 (0.36, 2.95)* 0.71 (0.32, 1.81)
IL-6, pg/mL 0.52 (0.33, 0.80) 1.52 (0.54, 3.37)*** 1.03 (0.56, 1.79)***
IL-10, pg/mL 11.4 (6.6, 18.6) 15.8 (10.7, 38.7)* 19.3 (12.5, 31.3)***
TNF-α, pg/mL 2.32 (1.46, 3.75) 3.29 (1.99, 6.10)* 3.27 (2.18, 4.22)**
MIF, ng/mL 25.7 (21.4, 33.1) 49.3 (39.5, 79.0)** 46.2 (37.6, 58.2)**
vWF, μg/mL 7.56 (5.25, 12.50) 10.83 (7.68,19.36)** 11.32 (7.75,18.15)**
E-selectin +
EMP, (/μL)
154 (122, 185) 164 (129, 204) 132(109, 184)
Results were expressed as median (25, 75 percentile). *, **, *** vs. control
(p < 0.05, <0.01, <0.001), # vs. RA (p < 0.05). CRP: C-reactive protein; EMP: endothelial
microparticles; IBD: inflammatory bowel disease; IL-1β: interleukin-1β; IL-6:
interleukin-6; IL-10: interleukin-10; MIF: macrophage migration inhibitory factor; RA:
rheumatoid arthritis; TNF-α: tumour necrosis factor-α; vWF: von Willebrand factor.
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controls. Diastolic blood pressure was significantly higher
in IBD patients compared with controls. More RA patients
received anti-hypertensive treatment than controls or IBD
patients. FRS was significantly elevated in RA group
but not in IBD compared with the control group (Table 1).
Mean disease duration of RA patients was 9.2 ± 7.9 years.
The majority of RA patients were either asymptomatic or
experiencing only mild symptoms at the time of their as-
sessment. Only 17.5% of RA patients were experiencing
moderate or severe symptoms. Mean disease duration of
IBD patients was 11.5 ± 10.7 years. In CD group, average
disease score was 2.4, while in UC group, all but one pa-
tient had mild disease at the time of their cardiovascular
assessment. Thus, at the time of assessment, most patients
were effectively treated with regard to disease signs and
symptoms.
Inflammatory and endothelial markers, and vascular
properties
Levels of CRP, IL-1β, IL-6, IL-10, TNF-α, MIF and vWF
were elevated in both RA and IBD patients compared with
controls (Table 2). Whilst there was a tendency for E-
selectin+EMP to be elevated in the RA group, the differ-
ences failed to achieve statistical significance. The elevationTable 1 Demographic characteristics of subjects
Control
(n = 73)
RA (n = 43) IBD (n = 42)
Age, y 51 ± 10 55 ± 11 50 ± 10
Male, % 46 51 45
SBP, mmHg 118 ± 14 126 ± 13* 125 ± 17
DBP, mmHg 67 ± 10 74 ± 9** 74 ± 10**
Body mass index, kg/m2 25.6 ± 3.8 28.1 ± 5.8* 26.9 ± 6.1
Waist, cm 88.2 ± 11.7 96.0 ± 15.5* 92.3 ± 14.3
Diabetes, % 10 14 10
Total cholesterol, mmol/L 5.45 ± 0.86 5.30 ± 1.13 5.23 ± 1.20
LDL-C, mmol/L 3.45 ± 0.81 3.25 ± 1.12 3.19 ± 1.15
HDL-C, mmol/L 1.50 ± 0.33 1.44 ± 0.37 1.46 ± 0.45




Anti-HT treatment, % 8 37*** 9##
LLT, % 4 11 5
FBS, mmol/L 4.8 (4.5, 5.2) 4.9 (4.5, 5.4) 4.6 (4.4, 5.2)
FRS 2.0 (0, 4.5) 4.0 (1.0, 12.0)** 2.0 (0, 8.0)
Results were expressed as mean ± SD, or percentage or median (25, 75 percentile).
*,**,*** vs. control p < 0.05, <0.01, <0.001, respectively, ##, vs. RA p < 0.01. Anti-HT
treatment: anti-hypertensive treatment; ex-smoker: prior smokers who have not
smoked in the last 12 months; DBP: diastolic blood pressure; FBS: fasting blood
sugar; FRS: Framingham Risk Score; HDL-C: high-density lipoprotein cholesterol;
IBD: inflammatory bowel disease; LDL-C: low-density lipoprotein cholesterol; LLT:
lipid-lowering therapy; RA: rheumatoid arthritis; SBP: systolic blood pressure.of most inflammatory markers and vWF did not differ
significantly between RA and IBD, but the level of CRP
was significantly higher in RA compared to IBD. Since
data were non-normally distributed, we also did compari-
sons on Ln transformed data. The results of statistical
significance were almost identical to those presented in
Table 2. The only exception was that the difference in
Ln transformed E-selectin + EMP between RA and IBD
reached significant (p = 0.036).
MIF was increased in former or current smokers com-
pared with non-smokers (48.6 ng/mL (36.2, 59.9 ng/mL)
and 41.8 ng/mL (30.2, 59.1 ng/mL) vs. 33.3 ng/mL (25.4,
48.7 ng/mL), p = 0.026). Vascular measures for the 3 groups
are shown in Table 3. The minimum value of ABI was
modestly but significantly lower in IBD than controls but
other changes were not significant.
Correlations between inflammatory markers, vascular
properties, and traditional risk factors
In the whole population, significant correlations were
found between baPWV and MIF, TNF-α, CRP, and vWF
(Figure 1). Neither UT nor ABI correlated with any of
plasma markers. FRS also significantly correlated with CRP,
IL-6, TNF-α, MIF, and vWF (Figure 2). Significant correla-
tions existed between several inflammatory markers (and
vWF) and classical risk factors (Table 4). The inflammatory
markers were also highly auto-correlated (data not shown).Table 3 Comparisons of baPWV, ABI, and UT
Control RA IBD
baPWV (m/s) 1345 ± 264 1437 ± 216 1382 ± 259
ABI 1.11 ± 0.06 1.10 ± 0.08 1.07 ± 0.07*
UT (ms) 139.8 ± 14.0 143.1 ± 14.0 140.2 ± 17.6
Results were expressed as mean ± SD.*vs. control (p < 0.05). ABI: ankle-brachial
index; baPWV: brachial-ankle pulse wave velocity; IBD: inflammatory bowel
disease; RA: rheumatoid arthritis; UT: upstroke time of pulse wave.
Figure 1 The correlations between circulating markers and brachial-ankle pulse wave velocity (PWV). Correlation was assessed by Spearman
rank Correlation. CRP: C-reactive protein; MIF: macrophage migration inhibitory factor; TNF-α: tumour necrosis factor-α; vWF: von Willebrand factor.
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baPWV correlated with age (r = 0.737, p < 0.001), systolic
blood pressure (r = 0.616, p < 0.001) and triglycerides (r =
0.311, p < 0.001). baPWV was higher in diabetic subjects
than non-diabetic subjects (1570 ± 298 m/s vs. 1360 ±Figure 2 The correlations between circulating markers and the 10 year Fra
Correlation. CRP: C-reactive protein; IL-6: interleukin-6; MIF: macrophage migration248 m/s, p = 0.001). In multiple regression analyses, signifi-
cant determinants of baPWV were age, systolic blood pres-
sure, BMI, diabetes and triglycerides with overall r value of
0.866 (p < 0.001). Stepwise addition of each inflammatory
or endothelial marker to regression analyses including themingham risk score (FRS). Correlation was assessed by Spearman rank
inhibitory factor; TNF-α: tumour necrosis factor-α; vWF: von Willebrand factor.
Table 4 Correlations between inflammatory and endothelial markers and traditional risk factors
CRP IL-1β IL-6 IL-10 TNF-α MIF E-sel + EMP vWF
Age 0.081 -0.013 0.157 0.160* 0.005 0.136 0.018 0.240**
SBP 0.324*** 0.110 0.203* 0.235* 0.163* 0.303** 0.094 0.154
BMI 0.403*** -0.017 0.047 -0.029 0.049 0.072 0.186* 0.136
TG 0.254** -0.034 0.034 -0.043 -0.085 -0.263** 0.147 0.180*
*,**,*** indicate significance at p < 0.05, <0.01, <0.001, respectively. BMI: body mass index; CRP: C-reactive protein; EMP: endothelial microparticles; IBD: inflammatory
bowel disease; IL-1β: interleukin-1β; IL-6: interleukin-6; IL-10: interleukin-10; MIF: macrophage migration inhibitory factor; RA: rheumatoid arthritis; SBP: systolic
blood pressure; TG: triglycerides; TNF-α: tumour necrosis factor-α; vWF: von Willebrand factor. Statistically significant correlations are shown with bold typeface.
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were independently related to baPWV. Disease group
(either RA or IBD) was not a significant determinant of
baPWV.
In addition, patients on anti-hypertensive treatment
(n = 26) had higher average baPWV than those not on
anti-hypertensive treatment (n = 132) (1535 ± 48 vs. 1352 ±
22 (m/s), p = 0.001). Those on anti-hypertensive treatment
were older (59.6 ± 2.1 vs. 51.1 ± 0.9 years, p = 0.000), having
higher SBP (132 ± 2.7 vs. 120.9 ± 1.3 mmHg, p = 0.01), and
greater BMI (29.5 ± 1.1 vs. 26.0 ± 0.4, p = 0.002). They were
also more likely diabetic (26.9% vs. 7.5%, p = 0.009), and
tended to have higher TG (1.44 ± 0.11 vs. 1.15 ± 0.06, p =
0.06). Because of the associations shown above, anti-
hypertensive treatment was not significantly related to
PWV after adjusting for age, SBP, BMI, DM and TG in
the multiple regression analysis.
ABI was lower in women than men (1.08 ± 0.06 vs. 1.11 ±
0.07, p = 0.003) and in current smokers compared with
ex- and non-smokers (1.06 ± 0.07 vs. 1.10 ± 0.07). UT was
higher in women than men (145.2 ± 16.8 ms vs. 134.7 ±
10.2 ms, p <0.001) and in current and former smokers vs.
non-smokers (144.8 ± 15.1 ms and 144.1 ± 16.8 ms vs.
137.9 ± 13.3 ms, p = 0.029). In regression analyses in the
whole cohort, ABI was dependent on gender and smok-
ing (with an overall r = 0.312, p < 0.001) as was UT (r =
0.425, p < 0.001) but neither was correlated to any of the
inflammatory or endothelial markers. Disease group
(either RA or IBD) was a significant determinant for
ABI but not UT.
Discussion
In the present study, we have made several main ob-
servations. First, plasma levels of several inflammatory
markers and vWF were significantly but comparably ele-
vated in RA and IBD compared with controls, except for a
higher level of CRP in RA than IBD. Next, traditional car-
diovascular risk factors were more pronounced in RA
than IBD. Furthermore, whilst ABI was modestly but sig-
nificantly lower in IBD compared to controls, there were
no significant differences in baPWV amongst the 3 groups.
baPWV was mainly associated with traditional risk factors,
with age and systolic blood pressure making the most
significant contribution to baPWV. CRP, MIF, TNF-αand vWF significantly correlated with baPWV, but the cor-
relations disappeared after adjusting for main traditional risk
factors. We also observed significant associations between
traditional risk factors and several inflammatory markers.
It is well established that patients with RA are at an in-
creased risk of developing cardiovascular events and mor-
tality [6-8], however, the association between cardiovascular
disease and IBD is controversial. While some studies
showed that IBD was not related to an increased risk of
cardiovascular disease and mortality [9-11,22], other more
recent studies supported such association [12,23-25]. A re-
cent meta-analysis that included 33 studies enrolling 207,
814 patients and 5,774,898 controls has concluded that
patients with IBD are at major risk for venous thrombo-
embolism and mesenteric ischemia and, to a lesser degree,
arterial thromboembolism and ischemic heart disease.
However, IBD is not associated with an increase in the
risk of cardiovascular mortality [26]. In the present study,
we compared markers of inflammation and endothelial
dysfunction, traditional cardiovascular risk factors, and
baPWV and ABI between RA and IBD. The elevation of
a number of inflammation markers and vWF did not
differ significantly between RA and IBD, but the level
of CRP was significantly higher in RA than IBD. Notably,
CRP level is known to be affected by anti-inflammation
treatment such as biologics. However, CRP still remained
higher in RA than IBD even though more RA patients re-
ceived biologics than IBD patients at the time of their vas-
cular study. It is well known that CRP is both a predictor
and an independent risk factor for cardiovascular disease
and is a predictor of cardiovascular mortality in patients
with RA [27]. CRP < 1.0 μg/mL is generally regarded as low
risk, 1.0-2.99 μg/mL as intermediate risk and >3 μg/mL as
high risk for the development of cardiovascular disease in
subjects apparently free of such disease at baseline. In the
current cohort, 55.8% of RA patients and 26.2% of IBD pa-
tients had CRP > 3 μg/m in comparison with only 12.3% in
the control group. So, while our results confirm chronic
systemic inflammation in both RA and IBD, we do observe
a higher plasma level of CRP in RA, which may have some
pathological impact on cardiovascular disease. In addition,
although not statistically significant, IL-6 was 47.6% higher
in RA than in IBD. IL-6 levels also show a graded relation-
ship to future cardiac risk [28] with subjects in the 3rd and
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times and cutoff values being 1.47 and 2.28 pg/mL, respect-
ively. In the current cohort, 53% and 36.4% of RA pa-
tients had IL-6 > 1.47 pg/mL and >2.28 pg/mL, respectively,
whereas 32.4% and 18.4% of IBD patients had IL-6 >
1.47 pg/mL and IL6 > 2.28 pg/mL, respectively.
We also found that traditional cardiovascular risk factors
were more prevalent in RA compared to IBD. FRS, calcu-
lated based on age, male gender, smoking, systolic blood
pressure, total cholesterol, HDL-C, and anti-hypertensive
treatment, was significantly increased in RA but not in
IBD, compared with the control group. BMI, waist size,
and triglycerides were also increased only in RA, compared
to controls. Previous studies have also documented in-
creased prevalence of traditional risk factors in RA [6,29].
In contrast, only two traditional risk factors i.e. hyperten-
sion and smoking existed in IBD patients. Consistent with
our study, FRS was not increased in IBD in a previous
study [30]. Other than hypertension, elevated traditional
risk factors have not been confirmed in IBD [31]. BMI and
LDL-C were even lower in IBD [32], which may be due to
intestinal malabsorption. So, while chronic systemic in-
flammation in IBD supports its association with cardiovas-
cular risk, some unique features related to traditional risk
factors in IBD may alter such association. Take together,
more pronounced traditional risk factors and a higher
level of CRP in RA, compared to IBD, may contribute
to the different associations with ischemic heart disease
and cardiovascular mortality between RA and IBD, re-
ported in literature. Meanwhile, different focuses should
be placed when monitoring and modifying cardiovascular
risk factors in patients with RA and IBD.
We also observed significant associations between in-
flammation and traditional risk factors. Several inflam-
matory markers significantly correlated with FRS, as well
as with individual traditional risk factor. Notably, the asso-
ciations with CRP were strongest. Given the cross-sectional
nature of this study, it is impossible to determine whether
these associations are causal. However, inflammation has
been suggested to play a role in the pathogenesis of hyper-
tension [33]. There is evidence showing that inflammation
causes obesity [34]. Insulin resistance is known to be in-
duced by inflammation arising from adipose tissue [35,36]
and elevated levels of CRP and IL-6 are shown to pre-
dict the development of diabetes [37]. Inflammation also
induces decreased HDL-C and subsequent hypertriglyc-
eridemia [38]. Reverse cholesterol transport, a protective
process against atherosclerosis, is adversely affected by
inflammation [39]. So, the elevations in inflammatory
markers may partly underlie the elevation seen in
traditional risk factors. The elevation of CRP in RA
could contribute to elevated traditional risk factors
and increased susceptibility to cardiovascular disease
in RA.Arterial stiffness is both a marker and a risk factor for
cardiovascular disease [13-15] and inflammation plays an
important role in the pathogenesis of arterial stiffness. In-
creased aortic PWV was reported in patients with RA in a
number of studies [40,41] and in patients with IBD in a
small study [42]. However, we did not observe a significant
increase in mean baPWV in either RA or IBD. Similarly,
some other studies did not find increased PWV in RA [43],
or in IBD [32]. Our results may suggest that increased
traditional risk factors, but not the effect of systemic in-
flammation on arterial stiffness, are more likely to underlie
the reported increased risk of cardiovascular disease in
RA. Previous studies have shown associations between
CRP and PWV in healthy subjects [44], hypertensive [45]
and RA patients [40]. The increase in aortic PWV in RA
was reduced by anti-TNF-α or anti-IL-6 therapy without
change in blood pressure [40,41]. In the present study, we
found that CRP, MIF, TNF-α and vWF significantly corre-
lated with baPWV, however, the correlations disappeared
after adjusting for main traditional risk factors. The major
univariate determinants of baPWV were age (r = 0.737)
and systolic blood pressure (r = 0.616), and after includ-
ing BMI, triglycerides and diabetes, the overall r was 0.866,
suggesting that traditional cardiovascular risk factors, ra-
ther than inflammatory markers or vWF, are predictors of
baPWV. However, in healthy subjects without inflamma-
tory disease, associations between CRP and PWV (includ-
ing baPWV) existed after adjustment for traditional risk
factors [44,46]. The clear associations between traditional
risk factors and inflammatory markers in this study likely
account for, in part, the failure of the inflammatory
markers to be statistically significant in multiple regression.
Moreover, medication, particularly disease modifying drugs,
which may reduce inflammation and stiffness, probably
weaken the link between inflammation and arterial stiffness.
Taken together, in chronic inflammatory patients without
established cardiovascular disease, arterial stiffness is associ-
ated with traditional risk factors, pointing to the import-
ance of modifying traditional risk factors in inflammatory
disorders.
The prognostic significance of peripheral arterial disease
is well recognised. The accepted ABI demarcation of
abnormality is ≤0.9 and prognosis for vascular events
and total mortality becomes progressively worse with lower
ABI values. However values of 0.9-1.1 are also predict-
ive of increased mortality [47] and likely represent the
evidence of early vascular disease. We found that ABI
was modestly but significantly lower in IBD patients
than controls, which may suggest a higher incidence
of early stage of peripheral arterial disease in IBD than
RA. Significant determinants of ABI were limited to
gender and smoking but not any of inflammatory markers.
Peripheral arterial disease is known to be particularly re-
lated to cigarette smoking [48] and it is noteworthy that
Fan et al. Journal of Inflammation 2014, 11:29 Page 8 of 9
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had never smoked.
This study has several limitations. First, we measured
baPWV to assess arterial stiffness. We cannot exclude the
possibility that the results from aortic PWV may be differ-
ent. However, baPWV has been shown to strongly correl-
ate with carotid-femoral PWV with r values of 0.73-0.79
being reported [49-51]. In multiple regression analysis
about 58% of the variance of baPWV was attributable to
carotid-femoral PWV and about 23% to femoral-ankle
PWV [51]. Age and blood pressure are major and similar
determinants of both carotid-femoral PWV and baPWV.
Whilst carotid-femoral PWV is determined by the proper-
ties of the aorta, baPWV also includes the peripheral arter-
ial circulation which may contribute to its ability to act
as a risk marker. Thus, correlation with FRS was 0.48
for carotid-femoral PWV and 0.63 for baPWV although
the two measures exhibited comparable predictive values
for stroke and coronary artery disease [49]. A meta-analysis
of more than 8000 subjects confirmed the predictive
value of baPWV for cardiovascular disease. An increase
in baPWV of 1 m/s corresponded to an increase of 12%,
13% and 6% in total cardiovascular events, cardiovascular
mortality and total mortality, respectively [52]. Thus,
whilst use of baPWV could be a potential limitation of
the study there is substantial evidence that baPWV
does reflect the response of the arteries to risk factors.
In addition, baPWV is a simple and automatic measure,
which can be done in an outpatient clinic setting, as part
of routine care. Another potential limitation of the study
is relatively small group size especially for the disease
groups. Despite this, significant differences in traditional
risk factors and CRP were evident between the groups and
the overall r value for baPWV in multiple regression ana-
lysis was > 0.86.
In conclusion, RA has a higher level of CRP and more
pronounced traditional risk factors, compared to IBD,
which may contribute to the different associations with
cardiovascular disease and mortality reported. Traditional
risk factors, but not inflammatory markers, are the major
parameters associated with arterial stiffness even in a co-
hort with evident systemic inflammation. Our data suggest
that it is important to control traditional risk factors in pa-
tients with these inflammatory disorders.
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